维得利珠单抗治疗溃疡性结肠炎和克罗恩病的长期安全性:前瞻性观察研究
这项前瞻性多中心观察性研究比较了维得利珠单抗与其他生物制剂在溃疡性结肠炎或克罗恩病患者中的长期安全性,主要终点为严重感染。全分析集共5008例,平均随访37.4个月,结果显示维得利珠单抗未发现新的安全性信号,安全性和有效性与其他生物制剂相当。
要点
- 维得利珠单抗组与全因严重感染风险无显著差异。
- 未观察到进行性多灶性白质脑病病例。
- 妊娠相关安全性未发现异常。
核心结论
- 维得利珠单抗未发现新的安全性信号,安全性和有效性与其已知特征一致。
研究设计与样本
- 前瞻性、观察性、多中心队列研究,纳入开始使用维得利珠单抗或其他生物制剂的溃疡性结肠炎或克罗恩病患者,全分析集5008例。
主要发现
- 维得利珠单抗组死亡18例,其他生物制剂组死亡13例;未观察到与妊娠相关的安全性问题,也未观察到进行性多灶性白质脑病病例。
- 两队列的临床有效性相当,且与维得利珠单抗其他前瞻性观察研究中的水平相似。
临床怎么用
- 在溃疡性结肠炎和克罗恩病中长期使用维得利珠单抗时,严重感染风险与其他生物制剂相当,可参考已知安全性特征进行临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: This postauthorization safety study compared long-term safety of vedolizumab or other biologics in patients with ulcerative colitis (UC) or Crohn's disease (CD). METHODS: This was a prospective, observational, multicenter cohort study in patients with UC or CD starting treatment with vedolizumab or other biologics (NCT02674308, EUPAS6469). The primary safety outcome was serious infections compared between cohorts using a Cox proportional hazards model adjusted by propensity score. Clinical effectiveness was a secondary outcome. RESULTS: The full analysis set comprised 5008 patients (vedolizumab: n = 2502; other biologic: n = 2506) and mean follow-up duration was 37.4 ± 14.1 months. Patients in the vedolizumab group had greater age, duration of disease, and concomitant medication use at baseline, indicating more advanced disease. In patients with UC, the incidence rate per 100 person-years of serious infections was 5.5 (95% confidence interval [CI], 4.7-6.5) (vedolizumab) and 7.0 (95% CI, 5.8-8.5) (other biologic), with an adjusted hazard ratio of 0.89 (95% CI, 0.69-1.15) (P = .38). In patients with CD, corresponding findings were 7.9 (95% CI, 6.8-9.1) (vedolizumab) and 6.5 (95% CI, 5.7-7.3) (other biologic) with adjusted hazard ratio of 1.15 (95% CI, 0.95-1.40) (P = .16). There were no safety issues relating to pregnancy, and no cases of progressive multifocal leukoencephalopathy were observed. There were 18 deaths in the vedolizumab group and 13 in the other biologics group. Clinical effectiveness was comparable between cohorts and was similar to the levels seen in other prospective observations of vedolizumab. CONCLUSIONS: There was no new safety signal identified in relation to vedolizumab. Results regarding safety and effectiveness were consistent with the known profile of vedolizumab.
引用
- Louis E, Sebastian S, Siegmund B, et al. Long-Term Safety of Vedolizumab in Patients With Ulcerative Colitis/Crohn's Disease: A Prospective Observational Study. Clin Gastroenterol Hepatol. 2025. PMID: 41092971. doi:10.1016/j.cgh.2025.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。